These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 10178663)

  • 1. The (near) equivalence of cost-effectiveness and cost-benefit analyses. Fact or fallacy?
    Donaldson C
    Pharmacoeconomics; 1998 Apr; 13(4):389-96. PubMed ID: 10178663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conditions for the near equivalence of cost-effectiveness and cost-benefit analyses.
    Bala MV; Zarkin GA; Mauskopf JA
    Value Health; 2002; 5(4):338-46. PubMed ID: 12102696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in the methods of cost-benefit analysis in healthcare. Matching the art to the science.
    McIntosh E; Donaldson C; Ryan M
    Pharmacoeconomics; 1999 Apr; 15(4):357-67. PubMed ID: 10537954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The decision rules of cost-effectiveness analysis.
    Karlsson G; Johannesson M
    Pharmacoeconomics; 1996 Feb; 9(2):113-20. PubMed ID: 10160090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimation, power and sample size calculations for stochastic cost and effectiveness analysis.
    Walter SD; Gafni A; Birch S
    Pharmacoeconomics; 2007; 25(6):455-66. PubMed ID: 17523751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of patient preferences in cost-effectiveness analysis: a conflict of values?
    Brazier JE; Dixon S; Ratcliffe J
    Pharmacoeconomics; 2009; 27(9):705-12. PubMed ID: 19757864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Information created to evade reality (ICER): things we should not look to for answers.
    Birch S; Gafni A
    Pharmacoeconomics; 2006; 24(11):1121-31. PubMed ID: 17067196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analyses alongside randomised clinical trials.
    Gray AM
    Clin Trials; 2006; 3(6):538-42. PubMed ID: 17170038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statistical comments.
    Kikushi T
    Value Health; 2008; 11(2):345; discussion 346. PubMed ID: 18380647
    [No Abstract]   [Full Text] [Related]  

  • 10. Methods for integrating medication compliance and persistence in pharmacoeconomic evaluations.
    Hughes D; Cowell W; Koncz T; Cramer J;
    Value Health; 2007; 10(6):498-509. PubMed ID: 17970932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defining types of economic evaluation.
    Ngorsuraches S
    J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S21-7. PubMed ID: 19255985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacoeconomic research.
    Postma MJ
    Pharm World Sci; 2003 Dec; 25(6):245-6. PubMed ID: 14689810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Benefit Analysis versus Cost-Effectiveness Analysis from a Societal Perspective in Healthcare.
    Brent RJ
    Int J Environ Res Public Health; 2023 Mar; 20(5):. PubMed ID: 36901658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Handling input correlations in pharmacoeconomic models.
    Naveršnik K; Rojnik K
    Value Health; 2012 May; 15(3):540-9. PubMed ID: 22583465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness as an outcome in randomized clinical trials.
    Hlatky MA; Owens DK; Sanders GD
    Clin Trials; 2006; 3(6):543-51. PubMed ID: 17170039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-benefit and cost-effectiveness analysis of drug therapy.
    Dao TD
    Am J Hosp Pharm; 1985 Apr; 42(4):791-802. PubMed ID: 3925768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Methods for analyzing uncertainty].
    Ferriols R; Alós M
    Farm Hosp; 2011 May; 35 Suppl 2():3-9. PubMed ID: 22445503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Introduction to the theory of pharmaco-economics].
    Kurz X; Dresse A
    Rev Med Liege; 1998 May; 53(5):230-5. PubMed ID: 9689873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Economic analyses of health care. Cost benefit analyses promote better use of resources].
    Kristiansen IS
    Tidsskr Nor Laegeforen; 1990 Aug; 110(18):2377-81. PubMed ID: 2120789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methods for determining cost-benefit ratios for pharmaceuticals in Germany.
    von der Schulenburg J; Vauth C; Mittendorf T; Greiner W
    Eur J Health Econ; 2007 Sep; 8 Suppl 1():S5-31. PubMed ID: 17582539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.